Titre : Hypoglycémiants

Hypoglycémiants : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hypoglycémiants : Questions médicales les plus fréquentes", "headline": "Hypoglycémiants : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hypoglycémiants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-16", "dateModified": "2025-03-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hypoglycémiants" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Effets physiologiques des médicaments", "url": "https://questionsmedicales.fr/mesh/D045505", "about": { "@type": "MedicalCondition", "name": "Effets physiologiques des médicaments", "code": { "@type": "MedicalCode", "code": "D045505", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs des glycoside hydrolases", "alternateName": "Glycoside Hydrolase Inhibitors", "url": "https://questionsmedicales.fr/mesh/D065089", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des glycoside hydrolases", "code": { "@type": "MedicalCode", "code": "D065089", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.249" } } }, { "@type": "MedicalWebPage", "name": "Agonistes des récepteurs de l'amyline", "alternateName": "Amylin Receptor Agonists", "url": "https://questionsmedicales.fr/mesh/D065091", "about": { "@type": "MedicalCondition", "name": "Agonistes des récepteurs de l'amyline", "code": { "@type": "MedicalCode", "code": "D065091", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.374" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de la dipeptidyl-peptidase IV", "alternateName": "Dipeptidyl-Peptidase IV Inhibitors", "url": "https://questionsmedicales.fr/mesh/D054873", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la dipeptidyl-peptidase IV", "code": { "@type": "MedicalCode", "code": "D054873", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.500" } } }, { "@type": "MedicalWebPage", "name": "Secrétagogues à l'insuline", "alternateName": "Insulin Secretagogues", "url": "https://questionsmedicales.fr/mesh/D000092005", "about": { "@type": "MedicalCondition", "name": "Secrétagogues à l'insuline", "code": { "@type": "MedicalCode", "code": "D000092005", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.625" } } }, { "@type": "MedicalWebPage", "name": "Agonistes du PPAR gamma", "alternateName": "PPAR-gamma Agonists", "url": "https://questionsmedicales.fr/mesh/D000092126", "about": { "@type": "MedicalCondition", "name": "Agonistes du PPAR gamma", "code": { "@type": "MedicalCode", "code": "D000092126", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.688" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs du cotransporteur sodium-glucose de type 2", "alternateName": "Sodium-Glucose Transporter 2 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000077203", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du cotransporteur sodium-glucose de type 2", "code": { "@type": "MedicalCode", "code": "D000077203", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.422.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Hypoglycémiants", "alternateName": "Hypoglycemic Agents", "code": { "@type": "MedicalCode", "code": "D007004", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nunzio Cardullo", "url": "https://questionsmedicales.fr/author/Nunzio%20Cardullo", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Giuseppe Floresta", "url": "https://questionsmedicales.fr/author/Giuseppe%20Floresta", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Vera Muccilli", "url": "https://questionsmedicales.fr/author/Vera%20Muccilli", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Antonio Rescifina", "url": "https://questionsmedicales.fr/author/Antonio%20Rescifina", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Corrado Tringali", "url": "https://questionsmedicales.fr/author/Corrado%20Tringali", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes.", "datePublished": "2022-08-05", "url": "https://questionsmedicales.fr/article/35930205", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00018-022-04481-1" } }, { "@type": "ScholarlyArticle", "name": "The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.", "datePublished": "2023-05-13", "url": "https://questionsmedicales.fr/article/37179266", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00432-023-04709-y" } }, { "@type": "ScholarlyArticle", "name": "Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35506216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocd.15039" } }, { "@type": "ScholarlyArticle", "name": "The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1", "datePublished": "2022-07-22", "url": "https://questionsmedicales.fr/article/35935985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.830606" } }, { "@type": "ScholarlyArticle", "name": "Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36801909", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-29971-5" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Effets physiologiques des médicaments", "item": "https://questionsmedicales.fr/mesh/D045505" }, { "@type": "ListItem", "position": 5, "name": "Hypoglycémiants", "item": "https://questionsmedicales.fr/mesh/D007004" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hypoglycémiants - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hypoglycémiants", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hypoglycémiants", "description": "Comment diagnostiquer une hypoglycémie ?\nQuels tests sont utilisés pour le diabète ?\nQuels symptômes indiquent une hypoglycémie ?\nQuand consulter un médecin pour hypoglycémie ?\nQuel rôle joue l'HbA1c dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hypoglycémiants", "description": "Quels sont les signes d'une hypoglycémie ?\nComment reconnaître une hypoglycémie sévère ?\nLes symptômes varient-ils selon les personnes ?\nQuels symptômes nécessitent une intervention rapide ?\nLes symptômes peuvent-ils être confondus avec d'autres ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hypoglycémiants", "description": "Comment prévenir l'hypoglycémie ?\nQuel rôle joue l'exercice dans la prévention ?\nLes patients doivent-ils surveiller leur glycémie ?\nComment éduquer les patients sur l'hypoglycémie ?\nLes régimes alimentaires peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hypoglycémiants", "description": "Quels sont les principaux hypoglycémiants ?\nComment administrer du glucose en cas d'hypoglycémie ?\nQuels sont les effets secondaires des hypoglycémiants ?\nComment ajuster le traitement hypoglycémiant ?\nLes hypoglycémiants sont-ils efficaces pour tous ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hypoglycémiants", "description": "Quelles sont les complications de l'hypoglycémie ?\nL'hypoglycémie peut-elle entraîner des séquelles ?\nComment l'hypoglycémie affecte-t-elle la qualité de vie ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme de l'hypoglycémie ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hypoglycémiants", "description": "Quels sont les facteurs de risque d'hypoglycémie ?\nL'âge influence-t-il le risque d'hypoglycémie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress peut-il aggraver l'hypoglycémie ?\nLes médicaments peuvent-ils influencer le risque ?", "url": "https://questionsmedicales.fr/mesh/D007004?mesh_terms=Programmed+Cell+Death+1+Receptor&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une hypoglycémie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'hypoglycémie est diagnostiquée par des tests de glycémie inférieure à 70 mg/dL." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diabète ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent la glycémie à jeun, l'HbA1c et le test de tolérance au glucose." } }, { "@type": "Question", "name": "Quels symptômes indiquent une hypoglycémie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent tremblements, sueurs, confusion et palpitations." } }, { "@type": "Question", "name": "Quand consulter un médecin pour hypoglycémie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si les symptômes persistent ou s'aggravent." } }, { "@type": "Question", "name": "Quel rôle joue l'HbA1c dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'HbA1c évalue le contrôle glycémique sur 2-3 mois, utile pour le diagnostic du diabète." } }, { "@type": "Question", "name": "Quels sont les signes d'une hypoglycémie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent fatigue, irritabilité, faim intense et vertiges." } }, { "@type": "Question", "name": "Comment reconnaître une hypoglycémie sévère ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une hypoglycémie sévère peut provoquer des convulsions, une perte de conscience ou un coma." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les personnes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier d'une personne à l'autre en fonction de la sensibilité." } }, { "@type": "Question", "name": "Quels symptômes nécessitent une intervention rapide ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes graves comme confusion, convulsions ou perte de conscience nécessitent une aide immédiate." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être confondus avec ceux d'autres conditions comme l'anxiété ou l'AVC." } }, { "@type": "Question", "name": "Comment prévenir l'hypoglycémie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Prévenir l'hypoglycémie nécessite une alimentation équilibrée et un suivi régulier de la glycémie." } }, { "@type": "Question", "name": "Quel rôle joue l'exercice dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier aide à réguler la glycémie et à prévenir les épisodes d'hypoglycémie." } }, { "@type": "Question", "name": "Les patients doivent-ils surveiller leur glycémie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la surveillance régulière de la glycémie est essentielle pour prévenir l'hypoglycémie." } }, { "@type": "Question", "name": "Comment éduquer les patients sur l'hypoglycémie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation doit inclure la reconnaissance des symptômes et les mesures à prendre en cas d'hypoglycémie." } }, { "@type": "Question", "name": "Les régimes alimentaires peuvent-ils aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un régime alimentaire équilibré et riche en fibres peut aider à stabiliser la glycémie." } }, { "@type": "Question", "name": "Quels sont les principaux hypoglycémiants ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux hypoglycémiants incluent la metformine, les sulfonylurées et les inhibiteurs DPP-4." } }, { "@type": "Question", "name": "Comment administrer du glucose en cas d'hypoglycémie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le glucose peut être administré par voie orale ou intraveineuse selon la gravité." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des hypoglycémiants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des nausées, des diarrhées et des hypoglycémies." } }, { "@type": "Question", "name": "Comment ajuster le traitement hypoglycémiant ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement doit être ajusté en fonction des niveaux de glycémie et des symptômes." } }, { "@type": "Question", "name": "Les hypoglycémiants sont-ils efficaces pour tous ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur efficacité peut varier selon le type de diabète et la réponse individuelle." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hypoglycémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques, des accidents vasculaires cérébraux et des chutes." } }, { "@type": "Question", "name": "L'hypoglycémie peut-elle entraîner des séquelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des épisodes répétés peuvent causer des dommages neurologiques permanents." } }, { "@type": "Question", "name": "Comment l'hypoglycémie affecte-t-elle la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'hypoglycémie fréquente peut entraîner une anxiété accrue et une diminution de la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles si l'hypoglycémie est traitée rapidement." } }, { "@type": "Question", "name": "Quels sont les risques à long terme de l'hypoglycémie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les risques à long terme incluent des troubles cognitifs et une augmentation du risque cardiovasculaire." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'hypoglycémie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent un traitement intensif du diabète, une alimentation irrégulière et l'alcool." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'hypoglycémie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de souffrir d'hypoglycémie en raison de la sensibilité accrue." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de diabète peuvent augmenter le risque d'hypoglycémie." } }, { "@type": "Question", "name": "Le stress peut-il aggraver l'hypoglycémie ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut affecter la glycémie et augmenter le risque d'hypoglycémie." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils influencer le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments, comme les bêta-bloquants, peuvent masquer les symptômes d'hypoglycémie." } } ] } ] }

Sources (10000 au total)

The significance of the microlymphangiogenesis, microangiogenesis, and combined detection of programmed cell death-1 protein (PD-1)/ki67 in gastric cancer tissues.

To investigate the relationship between the microlymphangiogenesis, microangiogenesis, and combined detection of the programmed cell death-1 protein (PD-1)/ki67 in patients with gastric cancer as well... Immunohistochemistry was used to detect the microlymphatic density (MLD) and microvessel density (MVD) in the central and peripheral zones in 92 cases of gastric cancer, along with the number of PD-1-... The central zone of the gastric cancer tissue contained fewer atretic cord-like lymphatic vessels than the peripheral zone, while the peripheral zone contained an increased number of lymphatic vessels... The detection of the MLD and MVD as well as the positive expression of PD-1 and ki67 in gastric cancer tissue are important reference indicators for judging the prognosis of gastric cancer....

Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients?

Early detection of psoriasis is still an open discussion. Psoriatic lesions are characterized by red/scaly plaques affecting different body-sites.... To evaluate the levels of programmed cell death protein-1(PD-1) and Angiopoietins-2(Ang-2) in serum, lesional, and perilesional of psoriatic patients and correlate them with controls and disease sever... Serum samples were obtained from 40 participants subdivided equally into psoriatic and healthy controls, 4 mm punch_biopsy equally from lesional and perilesional skin of individuals. PD-1/ANG-2 ELISA ... Serum and tissue levels of PD-1 and Ang-2 were overexpressed in psoriatic patients compared with controls. There was a statistical difference between patients and controls in level of PD-1(serum and t... PD-1 and ANG-2 can be highly recommended to determine the severity of psoriasis....

Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment.

Programmed cell death protein 1 (PD-1)-expressing T cells are expanded in individuals with established rheumatoid arthritis (RA). However, little is known about their functional role in the pathogenes...

A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1.

Little is known about how microbiota regulate innate-like γδ T cells or how these restrict their effector functions within mucosal barriers, where microbiota provide chronic stimulation. Here, we show...

Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.

Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted the... Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-li... In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinic...

An Immunochromatographic Test Strip for Rapid Quantitative Control of Monoclonal Antibodies against Programmed Cell Death Protein 1.

Cancer is one of the major public health challenges in the world, which is characterized by rapid progression and high mortality. Immunotherapy, represented by PD-1 monoclonal antibody, has significan...